North America Virus-like Particles Market

Market Introduction

The North America virus-like particles market analysis is based on three major countries: the US, Canada, and Mexico. Among North America provinces, US holds the largest size of the VLP's market due to reported viral infections, for example, variant influenza viruses. According to the Centers for Disease Control and Prevention (CDC), the majority of the conditions of variant viruses have mainly occurred in children aged 18 years or younger with the onset of illness, according to the report by the Centers for Disease Control and Prevention (CDC). Additionally, consistent R&D activities to manufacture live attenuated vaccines by the biopharmaceutical company positively impact the market growth.

In the North American provinces, the US was the most affected country due to COVID-19. This was due to the US showing an uneven response during the onset of COVID-19 coupled with insufficiencies in testing resources. To overcome the transmission rate of COVID-19, the development of the vaccine was on edge for all biopharmaceutical companies with a high focus on recombinant COVID-19 vaccines. As recombinant vaccines include recombinant spike protein vaccines, recombinant receptor-binding domain vaccines, and virus-like particles, it has gained high importance. Also, the development of more effective and targeted forms of VLP by modification of the surface of the particles in a fashion that they can be introduced into specific cells or tissues is likely to grow in the forthcoming years. Recent advances in the production of VLP's involve the different types of expression systems for the development as well as application of vaccines in the prevention of infectious diseases. In the North American region, countries where COVID-19 vaccines are currently being developed, including the US, Canada, and Cuba. Among these countries, the US has eleven vaccines, while Canada and Cuba possess three vaccines. Additionally, there are six protein subunit vaccines comprising of VLPs, five vector vaccines, and five nucleic acid vaccines. But the manufacturing of virus-like particles still remains challenging in terms of design, purification, and storage. Challenges are majorly associated with the bioprocessing technique that deals with respiratory issues. However, with strong advancement in technology it ultimately develops a series of novel, stable, and efficient VLP based vaccine candidates in the near future.

North America Virus-like Particles Strategic Insights

Strategic insights for the North America Virus-like Particles provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Virus-like Particles Report Scope

North America Virus-like Particles Regional Insights

The geographic scope of the North America Virus-like Particles refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The virus-like particles market in North America is expected to grow from US$ 1,928.37 million in 2021 to US$ 3,312.49 million by 2028; it is estimated to grow at a CAGR of 8.0% from 2021 to 2028. Various players in the healthcare market and research organizations are actively involved in product innovations and developments. The use of virus-like particles is an emerging approach used in the biopharmaceuticals industry. As virus-like particles lack the viral content, they are easier to handle than the actual viral components. The VLPs can be used for aiding drug delivery, imaging, immunotherapy, and theragnostic. For instance, as per a study published in the NCBI in June 2020, VLP can be used in the form of nanoparticles in applications such as photothermal therapy, PET and CT imaging, MRI contrast agent carriers, optical imaging, inflammatory and autoimmune disease vaccines, cancer immunotherapy, and small molecule drug delivery (in cancer therapy). Thus, such potential applications of VLPs are expected to provide growth opportunities to market players during the forecast period.

Key Market Segments

In terms of product type, the hepatitis segment accounted for the largest share of the North America virus-like particles market in 2021. In terms of source, the yeast segment accounted for the largest share of the North America virus-like particles market in 2021. In term of application, vaccines segment held a larger market share of the virus-like particles market in 2021.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the virus-like particles market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Merck & Co., Inc.; GlaxoSmithKline plc.; Pfizer Inc.; Sanofi; Serum Institute of India Pvt. Ltd.; BHARAT BIOTECH; LG Chem; VBI Vaccines Inc.; and Dynavax Technologies among others.

Reasons to buy report

• To understand the North America virus-like particles market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for North America virus-like particles market
• Efficiently plan M&A and partnership deals in North America virus-like particles market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America virus-like particles market
• Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.

North America Virus-like Particles Market Segmentation

North America Virus-like Particles Market – By Product type

• Hepatitis
• Cancer/HPV
• Gaucher Disease

North America Virus-like Particles Market – By Source

• Yeast
• Insect Cell
• Plant
• Others

North America Virus-like Particles Market – By

Application

• Vaccines
• Therapeutics

North America Virus-like Particles Market – By

Country

• US
• Canada  
• Mexico     

North America Virus-like Particles Market – Companies Mentioned

• Merck & Co., Inc.                                                       
• GlaxoSmithKline plc.
• Pfizer Inc.                                                                    
• Sanofi                                                                           
• Serum Institute of India Pvt. Ltd.                            
• BHARAT BIOTECH                                                      
• LG Chem                                                                    
• VBI Vaccines Inc.                                                        
• Dynavax Technologies